The toolbox of precision genome editing and delivery techniques continue to grow in 2024, enabling the community to make safer and more precise edits to a wider variety of disease targets. Translating these exciting technologies into viable therapeutic programs, however, relies on multidisciplinary technical and strategic expertise across areas in which the gene editing field is still in its infancy.
Join us at the 2024 Genome Editing Therapeutics Summit (formerly known as CRISPR 2.0) to develop, translate, and deliver novel gene editing technologies in the therapeutic setting. Data-driven talks, expert panel discussions, and interactive group discussions will cover the therapeutic application and drug development challenges of both:
- More established technologies, and their associated translational, nonclinical, clinical, and strategic challenges: including novel nucleases, base, prime, and multiplex editing techniques
- Ground-breaking precision tools enabling small and large alterations to the genome, including epigenome editing, recombinase and transposon-based technologies, and novel delivery vehicles
This is your unique opportunity to join Intellia Therapeutics, Prime Medicine, Beam Therapeutics and more this December in Boston, MA.
Registration is now open, with group discounts up to 20% and additional savings on offer. To translate exciting new gene editing technologies into viable therapeutic programs, multidisciplinary technical and strategic expertise is vital – don’t miss out.